Division of Haematology, University of Torino, AUO Città della Salute e della Scienza di Torino, Torino, Italy.
Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Br J Haematol. 2021 Jun;193(6):1105-1109. doi: 10.1111/bjh.17302. Epub 2021 Jan 6.
An updated survival analysis was conducted for the Phase II study O-12-M1 of melphalan flufenamide (melflufen) plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM) with two or more prior lines of therapy (including bortezomib and lenalidomide). Partial response or better was seen in 31%. After a 46-month median overall survival (OS) follow-up, melflufen plus dexamethasone had a median OS of 20·7 months (75th percentile OS, 47·5 months). The median time-to-next treatment for melflufen plus dexamethasone was 7·9 months. In summary, melflufen plus dexamethasone resulted in sustained long-term clinical benefit in patients with RRMM.
对先前接受过两线或以上治疗（包括硼替佐米和来那度胺）的复发/难治性多发性骨髓瘤（RRMM）患者进行了 II 期 O-12-M1 研究中 melphalan flufenamide（melflufen）联合地塞米松的更新生存分析。31%的患者观察到部分缓解或更好的反应。中位总生存期（OS）随访 46 个月后，melflufen 联合地塞米松的中位 OS 为 20.7 个月（75%的 OS，47.5 个月）。melflufen 联合地塞米松的下一次治疗中位时间为 7.9 个月。总之，melflufen 联合地塞米松在 RRMM 患者中产生了持续的长期临床获益。
Zotero 插件